Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial

NCT01620489 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01620489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01620489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2012
Completion date
August 20, 2013
Enrollment
279 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2